Register Now: Engineering LNP's Beyond the Liver for Genetic Medicines
|Articles|June 1, 2018

Fujifilm Opens Collaboration Center

FUJIFILM Diosynth Biotechnologies opens Cambridge, MA center to promote collaboration with biotech companies.

In advance of the 2018 BIO convention in Boston (June 5–7), FUJIFILM Diosynth Biotechnologies announced on May 31, 2018 the opening of its Cambridge (MA) Collaboration Center, featuring an atrium with event and meeting spaces designed to facilitate biotech partnership and education.

“With partnering as a key theme of the BIO convention, Fujifilm is thrilled to reveal its new Cambridge Collaboration Center, a space that will encourage partnership between biopharma leaders in Boston and beyond,” said Steve Bagshaw, chief executive officer of FUJIFILM Diosynth Biotechnologies in a press statement. “As a center for biotech innovation, at BIO 2018 Fujifilm will showcase its gene-therapy manufacturing and development solutions, which are designed to meet the needs of our partners to quickly and reliably support the delivery of advanced therapies to patients.”

Bagshaw will moderate a session at the BIO event, Delivering on the Promise of Gene Therapy, that will explore the way gene therapies are transforming patients’ lives, the challenges and opportunities in gene therapy scientific discovery, and new approaches in delivering new types of medicines to patients.

Source: FUJIFILM Diosynth Biotechnologies

 

 


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.